Prenetics Global (NASDAQ:PRE – Get Free Report) and Standard BioTools (NASDAQ:LAB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
Valuation and Earnings
This table compares Prenetics Global and Standard BioTools”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $21.74 million | 1.88 | -$62.72 million | ($3.99) | -1.12 |
| Standard BioTools | $106.34 million | 6.44 | -$74.66 million | ($0.71) | -2.59 |
Prenetics Global has higher earnings, but lower revenue than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Analyst Ratings
This is a summary of current ratings and target prices for Prenetics Global and Standard BioTools, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| Standard BioTools | 0 | 0 | 2 | 0 | 3.00 |
Prenetics Global currently has a consensus price target of $9.00, indicating a potential upside of 100.89%. Standard BioTools has a consensus price target of $2.88, indicating a potential upside of 56.25%. Given Prenetics Global’s higher possible upside, research analysts plainly believe Prenetics Global is more favorable than Standard BioTools.
Insider and Institutional Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 53.1% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Prenetics Global and Standard BioTools’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -191.73% | -16.02% | -13.23% |
| Standard BioTools | -79.92% | -27.05% | -15.52% |
Summary
Standard BioTools beats Prenetics Global on 8 of the 13 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Standard BioTools
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
